Co-expression of Fas (APO-1, CD95)/Fas ligand by BeWo and NJG choriocarcinoma cell lines

Raja Shekhar Gangaraju, A. Loganath, A. C. Roy, J. M. Mongelli

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective. Fas (CD95) is a transmembrane protein of the tumor necrosis factor receptor superfamily that induces apoptosis in susceptible cells on crosslinking by its ligand (FasL). The Fas loss of function and concurrent expression of its ligand (FasL) have been associated with malignant phenotype. In this study, we sought to investigate the hitherto undescribed expression of Fas and FasL on the immortalized human choriocarcinoma cell lines BeWo and NJG. Methods. Receptor and ligand expression was demonstrated using specific antibodies and multiple techniques including immunocytochemistry, confocal immunofluorescence microscopy, flow cytometry, immunoblots, and reverse transcription polymerase chain reaction (RT-PCR). Results. Data from this study indicate that human choriocarcinoma cell subtypes co-express both Fas and FasL. A specific cytoplasmic and membranous pattern of immunoreactivity was noted that was further confirmed at mRNA transcripts by RT-PCR. In addition, we provide evidence using flow cytometry that the Fas receptors are downregulated. The mean fluorescence intensities for NJG and BeWo were 1.47 ± 0.5 and 1.59 ± 0.4, while that for Fas-positive Jurkat cells was 25.6 ± 3.1. Conclusions. To our knowledge, this is the first report on the identification and constitutive co-expression of Fas and FasL in BeWo and NJG choriocarcinoma cells. Choriocarcinoma cells evade immune attack by downregulating the Fas receptor and by killing lymphocytes through expression of FasL. Taken together, our investigations suggest that the Fas/FasL system may represent a mechanism by which malignant trophoblasts become resistant to apoptosis, escape immune surveillance, and metastasize.

Original languageEnglish (US)
Pages (from-to)101-111
Number of pages11
JournalGynecologic Oncology
Volume91
Issue number1
DOIs
StatePublished - Oct 1 2003
Externally publishedYes

Fingerprint

Choriocarcinoma
Fas Ligand Protein
CD95 Antigens
Cell Line
Ligands
Reverse Transcription
Flow Cytometry
Down-Regulation
Apoptosis
Polymerase Chain Reaction
Jurkat Cells
Tumor Necrosis Factor Receptors
Trophoblasts
Fluorescence Microscopy
Confocal Microscopy
Fluorescence
Immunohistochemistry
Lymphocytes
Phenotype
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynecology

Cite this

Co-expression of Fas (APO-1, CD95)/Fas ligand by BeWo and NJG choriocarcinoma cell lines. / Gangaraju, Raja Shekhar; Loganath, A.; Roy, A. C.; Mongelli, J. M.

In: Gynecologic Oncology, Vol. 91, No. 1, 01.10.2003, p. 101-111.

Research output: Contribution to journalArticle

Gangaraju, Raja Shekhar ; Loganath, A. ; Roy, A. C. ; Mongelli, J. M. / Co-expression of Fas (APO-1, CD95)/Fas ligand by BeWo and NJG choriocarcinoma cell lines. In: Gynecologic Oncology. 2003 ; Vol. 91, No. 1. pp. 101-111.
@article{520d31be29654c419958a34c8a1a6083,
title = "Co-expression of Fas (APO-1, CD95)/Fas ligand by BeWo and NJG choriocarcinoma cell lines",
abstract = "Objective. Fas (CD95) is a transmembrane protein of the tumor necrosis factor receptor superfamily that induces apoptosis in susceptible cells on crosslinking by its ligand (FasL). The Fas loss of function and concurrent expression of its ligand (FasL) have been associated with malignant phenotype. In this study, we sought to investigate the hitherto undescribed expression of Fas and FasL on the immortalized human choriocarcinoma cell lines BeWo and NJG. Methods. Receptor and ligand expression was demonstrated using specific antibodies and multiple techniques including immunocytochemistry, confocal immunofluorescence microscopy, flow cytometry, immunoblots, and reverse transcription polymerase chain reaction (RT-PCR). Results. Data from this study indicate that human choriocarcinoma cell subtypes co-express both Fas and FasL. A specific cytoplasmic and membranous pattern of immunoreactivity was noted that was further confirmed at mRNA transcripts by RT-PCR. In addition, we provide evidence using flow cytometry that the Fas receptors are downregulated. The mean fluorescence intensities for NJG and BeWo were 1.47 ± 0.5 and 1.59 ± 0.4, while that for Fas-positive Jurkat cells was 25.6 ± 3.1. Conclusions. To our knowledge, this is the first report on the identification and constitutive co-expression of Fas and FasL in BeWo and NJG choriocarcinoma cells. Choriocarcinoma cells evade immune attack by downregulating the Fas receptor and by killing lymphocytes through expression of FasL. Taken together, our investigations suggest that the Fas/FasL system may represent a mechanism by which malignant trophoblasts become resistant to apoptosis, escape immune surveillance, and metastasize.",
author = "Gangaraju, {Raja Shekhar} and A. Loganath and Roy, {A. C.} and Mongelli, {J. M.}",
year = "2003",
month = "10",
day = "1",
doi = "10.1016/S0090-8258(03)00397-4",
language = "English (US)",
volume = "91",
pages = "101--111",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Co-expression of Fas (APO-1, CD95)/Fas ligand by BeWo and NJG choriocarcinoma cell lines

AU - Gangaraju, Raja Shekhar

AU - Loganath, A.

AU - Roy, A. C.

AU - Mongelli, J. M.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Objective. Fas (CD95) is a transmembrane protein of the tumor necrosis factor receptor superfamily that induces apoptosis in susceptible cells on crosslinking by its ligand (FasL). The Fas loss of function and concurrent expression of its ligand (FasL) have been associated with malignant phenotype. In this study, we sought to investigate the hitherto undescribed expression of Fas and FasL on the immortalized human choriocarcinoma cell lines BeWo and NJG. Methods. Receptor and ligand expression was demonstrated using specific antibodies and multiple techniques including immunocytochemistry, confocal immunofluorescence microscopy, flow cytometry, immunoblots, and reverse transcription polymerase chain reaction (RT-PCR). Results. Data from this study indicate that human choriocarcinoma cell subtypes co-express both Fas and FasL. A specific cytoplasmic and membranous pattern of immunoreactivity was noted that was further confirmed at mRNA transcripts by RT-PCR. In addition, we provide evidence using flow cytometry that the Fas receptors are downregulated. The mean fluorescence intensities for NJG and BeWo were 1.47 ± 0.5 and 1.59 ± 0.4, while that for Fas-positive Jurkat cells was 25.6 ± 3.1. Conclusions. To our knowledge, this is the first report on the identification and constitutive co-expression of Fas and FasL in BeWo and NJG choriocarcinoma cells. Choriocarcinoma cells evade immune attack by downregulating the Fas receptor and by killing lymphocytes through expression of FasL. Taken together, our investigations suggest that the Fas/FasL system may represent a mechanism by which malignant trophoblasts become resistant to apoptosis, escape immune surveillance, and metastasize.

AB - Objective. Fas (CD95) is a transmembrane protein of the tumor necrosis factor receptor superfamily that induces apoptosis in susceptible cells on crosslinking by its ligand (FasL). The Fas loss of function and concurrent expression of its ligand (FasL) have been associated with malignant phenotype. In this study, we sought to investigate the hitherto undescribed expression of Fas and FasL on the immortalized human choriocarcinoma cell lines BeWo and NJG. Methods. Receptor and ligand expression was demonstrated using specific antibodies and multiple techniques including immunocytochemistry, confocal immunofluorescence microscopy, flow cytometry, immunoblots, and reverse transcription polymerase chain reaction (RT-PCR). Results. Data from this study indicate that human choriocarcinoma cell subtypes co-express both Fas and FasL. A specific cytoplasmic and membranous pattern of immunoreactivity was noted that was further confirmed at mRNA transcripts by RT-PCR. In addition, we provide evidence using flow cytometry that the Fas receptors are downregulated. The mean fluorescence intensities for NJG and BeWo were 1.47 ± 0.5 and 1.59 ± 0.4, while that for Fas-positive Jurkat cells was 25.6 ± 3.1. Conclusions. To our knowledge, this is the first report on the identification and constitutive co-expression of Fas and FasL in BeWo and NJG choriocarcinoma cells. Choriocarcinoma cells evade immune attack by downregulating the Fas receptor and by killing lymphocytes through expression of FasL. Taken together, our investigations suggest that the Fas/FasL system may represent a mechanism by which malignant trophoblasts become resistant to apoptosis, escape immune surveillance, and metastasize.

UR - http://www.scopus.com/inward/record.url?scp=0141869077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141869077&partnerID=8YFLogxK

U2 - 10.1016/S0090-8258(03)00397-4

DO - 10.1016/S0090-8258(03)00397-4

M3 - Article

VL - 91

SP - 101

EP - 111

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -